ProKidney Corp
PROK2.530USD
-0.040-1.56%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
344.02MMarket Cap
LossP/E TTM
More Details of ProKidney Corp Company
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corp Info
Ticker SymbolPROK
Company nameProkidney Corp
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Number of employees204
Security typeOrdinary Share
Fiscal year-endJun 30
Address2000 Frontis Plaza Blvd
CityWINSTON-SALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27103
Phone13369997028
Websitehttps://prokidney.com/
Ticker SymbolPROK
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Company Executives of ProKidney Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. Ethan Holdaway
Mr. Ethan Holdaway
Investor Relations
Investor Relations
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. Ethan Holdaway
Mr. Ethan Holdaway
Investor Relations
Investor Relations
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Other
60.77%
Shareholders
Shareholders
Proportion
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Other
60.77%
Shareholder Types
Shareholders
Proportion
Corporation
23.56%
Hedge Fund
11.03%
Investment Advisor
9.77%
Investment Advisor/Hedge Fund
6.08%
Individual Investor
1.83%
Research Firm
0.90%
Endowment Fund
0.71%
Bank and Trust
0.03%
Family Office
0.02%
Other
46.07%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
2023Q2
223
59.02M
95.83%
-21.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tolerantia LLC
22.62M
16.75%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
9.14%
--
--
Jun 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.94%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
5.71M
4.23%
-4.33M
-43.14%
Jun 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.54%
--
--
Aug 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.81%
--
--
Aug 31, 2025
Bleichroeder LP
2.00M
1.48%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.57M
1.16%
-3.64M
-69.92%
Jun 30, 2025
Culleton (Bruce)
1.54M
1.14%
+1.54M
--
Mar 17, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
Schwab U.S. Small-Cap ETF
Proportion0.01%
ALPS Medical Breakthroughs ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ProKidney Corp?
The top five shareholders of ProKidney Corp are:
Tolerantia LLC holds 22.62M shares, accounting for 16.75% of the total shares.
Suvretta Capital Management, LLC holds 12.34M shares, accounting for 9.14% of the total shares.
Control Empresarial de Capitales, S.A. de C.V. holds 10.72M shares, accounting for 7.94% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 5.71M shares, accounting for 4.23% of the total shares.
BlackRock Mexico Operadora SA de CV SOFI holds 3.43M shares, accounting for 2.54% of the total shares.
Tolerantia LLC holds 22.62M shares, accounting for 16.75% of the total shares.
Suvretta Capital Management, LLC holds 12.34M shares, accounting for 9.14% of the total shares.
Control Empresarial de Capitales, S.A. de C.V. holds 10.72M shares, accounting for 7.94% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 5.71M shares, accounting for 4.23% of the total shares.
BlackRock Mexico Operadora SA de CV SOFI holds 3.43M shares, accounting for 2.54% of the total shares.
What are the top three shareholder types of ProKidney Corp?
The top three shareholder types of ProKidney Corp are:
Tolerantia LLC
Suvretta Capital Management, LLC
Control Empresarial de Capitales, S.A. de C.V.
Tolerantia LLC
Suvretta Capital Management, LLC
Control Empresarial de Capitales, S.A. de C.V.
How many institutions hold shares of ProKidney Corp (PROK)?
As of 2025Q3, 180 institutions hold shares of ProKidney Corp, with a combined market value of approximately 38.60M, accounting for 28.59% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -42.84%.
What is the biggest source of revenue for ProKidney Corp?
In --, the -- business generated the highest revenue for ProKidney Corp, amounting to -- and accounting for --% of total revenue.
